Sanofi and GSK announced the postponement of their adjuvant recombinant protein-
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in older adults. Phase 1/2 study interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years, but a low immune response in older adults likely due to an insufficient concentration of the antigen.
A recent challenge study in non-human primates performed with an improved antigen formulation demonstrated that the vaccine candidate could protect against lung pathology and lead to rapid viral clearance from the nasal passages and lungs, within 2 to 4 days. These results increase the Companies confidence in the capacity of the adjuvanted recombinant platform to deliver a highly efficient vaccine for all adults.
You May Interested In
Glow70/KLOW80 99% China Peptides Warehouse Direct Delivery Lyophilized Powder in Stock
$169/UNIT FOB
2026-10-12
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody
-
Sanofi and GSK will supply up to 300 million doses of COVID-19 vaccine to EU
-
Sanofi and GSK will supply up to 300 million doses of COVID-19 vaccine to EU
-
Wanhua’s Counter-Cyclical Expansion: A Gamble or a Strategic Move for the Next Cycle?
-
BASF Evaluates New MDI Production Complex in India, Secures Dahej Site
-
Henkel's Acquisition of Stahl Enters Regulatory Countdown: Will the €2.1 Billion Deal Go Through?
-
BASF Partners with Sinopec to Accelerate Application of Biomethane at Nanjing
-
Fracturing the Crown: BASF Antwerp’s 600-Job Cut and the Global Alarm
-
Procter & Gamble Posts Higher Profits on Strong Personal Care Sales and Recovery in China
-
Dafeng Haijianuo’s RMB 246 Million Technical Revamp Project Takes Shape, with Multiple Production Lines for Vitamin K1, Folic Acid, and Others Under Construction
Recommend Reading
-
![BASF Approves €1 Billion Share Buyback Program as Chemical Giant Prioritizes Capital Discipline]()
BASF Approves €1 Billion Share Buyback Program as Chemical Giant Prioritizes Capital Discipline
-
![BASF's Zhanjiang Plant Steam Cracking Unit Commences Operation]()
BASF's Zhanjiang Plant Steam Cracking Unit Commences Operation
-
![Unilever Reports Stronger Margins and Accelerated Portfolio Transformation in FY2025]()
Unilever Reports Stronger Margins and Accelerated Portfolio Transformation in FY2025
-
![Lilly Bets US$3 Billion on China While Simultaneously Cracking Down on the Gray Market for Weight-Loss Drugs]()
Lilly Bets US$3 Billion on China While Simultaneously Cracking Down on the Gray Market for Weight-Loss Drugs
-
![Isopropanol vs. Isopropyl Alcohol: Are They Different? (Uses & Safety)]()
Isopropanol vs. Isopropyl Alcohol: Are They Different? (Uses & Safety)
-
![Phenol Market Broadly Declines Since November, Then Gradually Stabilizes]()
Phenol Market Broadly Declines Since November, Then Gradually Stabilizes
-
![China's Propylene Oxide Market Prices Show a High-Level Correction (2.2-2.6)]()
China's Propylene Oxide Market Prices Show a High-Level Correction (2.2-2.6)
-
![This Week's Epichlorohydrin Market Prices Decline in China (2.2-2.6)]()
This Week's Epichlorohydrin Market Prices Decline in China (2.2-2.6)
-
![Ample Supply, Toluene Market Declines in China]()
Ample Supply, Toluene Market Declines in China
-
![Uses and Benefits of Sodium Selenite]()
Uses and Benefits of Sodium Selenite
